Adherence and/or discontinuation of imatinib mesylate in patients with chronic myeloid leukemia . Brazilian Journal of Pharmaceutical Sciences, [S. l.], v. 52, n. 4, p. 581–589, 2016. DOI: 10.1590/s1984-82502016000400001. Disponível em: https://revistas.usp.br/bjps/article/view/128373.. Acesso em: 3 may. 2024.